TGTX News & Events

Stock futures are up across the board as the S&P 500 and Nasdaq are hovering near fresh record highs again, helped by continued strength in AI-related stocks and improving sentiment around geopolitics.Treasury yields are pulling back slightly after a relentless surge over the past two weeks, with the 10-year yield moving down from recent highs near 4.5%. Markets are responding to signs that a potential Iran ceasefire or peace framework could ease oil-driven inflation pressure. Lower yields are giving technology and semiconductor stocks room to rebound.Crude prices dropped sharply after optimism around U.S.-Iran negotiations improved, with Brent crude falling back below $100 a barrel after briefly spiking during recent Strait of Hormuz tensions. AI enthusiasm continues dominating equity leadership. Semiconductor names and hyperscaler-related infrastructure plays remain the strongest part of the market, even as analysts increasingly debate whether the rally has become too narrow and valuation-sensitive.In pre-market trading, S&P 500 futures rose 0.23%, Nasdaq futures rose 0.73% and Dow futures rose 0.182%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -TG Therapeuticsup 2% after announcing its ENHANCE trial met its primary endpointUP AFTER EARNINGS -Dycomup 25%Bath & Body Worksup 12%Abercombie & Fitchup 4%DOWN AFTER EARNINGS -Zscalerdown 23%Movadodown 12%Capri Holdingsdown 2%Dick's Sportingdown 1%Bank of Montrealdown 1%

TG Therapeutics announced topline results from the Phase 3 ENHANCE trial, a randomized, double-blind study evaluating a consolidated single infusion regimen for initiation of Briumvi in adults with relapsing forms of multiple sclerosis. The trial met its primary endpoint, demonstrating bioequivalent drug exposure between the currently approved initiation dosing regimen of 150 mg on Day 1 and 450 mg on Day 15 and a consolidated single 600 mg infusion on Day 1, eliminating the need for a Day 15 infusion. Topline outcomes from the ENHANCE Phase 3 study are highlighted below, and full results are expected to be presented at an upcoming medical meeting. The trial met its primary endpoint, demonstrating bioequivalence between the new single Day 1 Briumvi infusion regimen and the currently approved initiation regimen administered on Days 1 and 15. Total drug exposure over 16 weeks was comparable between treatment arms, with a geometric mean ratio of approximately one and a 90% confidence interval within the protocol-defined bioequivalence range of 0.80 to 1.25. Secondary endpoints, including safety, B-cell depletion, and MRI outcomes, were consistent with prior Briumvi clinical studies and comparable between treatment arms through the primary assessment period with no new safety signals observed. Infusion-related reactions in both arms were lower than previously reported in the ULTIMATE I and II approval studies for Briumvi, with no Grade 3 or higher infusion reactions occurring in either arm. In addition, infusion-related reactions were statistically indistinguishable between treatment arms in this study with fewer infusion reactions observed in the consolidated single-infusion treatment arm.

Reports Q1 revenue $204.92M, consensus $201.21M. Michael S. Weiss, the Company's Chairman and Chief Executive Officer, stated, "We are off to a strong start in 2026, with BRIUMVI performance exceeding expectations and momentum continuing to build. Growth is being driven by strong underlying demand, record new patient starts, and consistent commercial execution- reinforcing our belief that we remain early in the adoption curve for BRIUMVI. Based on this performance, we are significantly increasing our full-year U.S. BRIUMVI revenue guidance to $885-900 million and continue to see the brand as having a multi-billion-dollar potential before considering the impact of a subcutaneous BRIUMVI currently under development. With multiple near-term clinical catalysts and ongoing efforts to expand the franchise, we believe BRIUMVI is well-positioned to become a leading therapy in MS and a durable, long-term growth driver for TG."